{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:47:21Z","timestamp":1759333641035},"reference-count":27,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Pyoderma gangrenosum (PG) is a chronic inflammatory disease that causes painful cutaneous ulcers that are difficult to treat. Currently, systemic immunosuppressants, often including prednisone, are the mainstay of therapy. Long\u2010term therapy with these agents is often required which exposes patients to possible adverse effects. An alternative treatment that is safe and effective is truly needed.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To study the efficacy and safety of alefacept, which inhibits T\u2010cell activation and selectively reduces the T\u2010cell population, for treatment of PG.<\/jats:p><jats:p><jats:bold>Method\u2002<\/jats:bold> In this prospective open\u2010label pilot study, four patients diagnosed with PG received weekly doses of 15\u00a0mg alefacept intramuscularly for 20\u00a0weeks with 12\u2010week treatment\u2010free follow\u2010up. The primary efficacy end point was the proportion of patients achieving remission as defined by a Physician Global Assessment (PGA) of \u2018clear\u2019 or \u2018almost clear.\u2019 Secondary endpoints included proportion of patients achieving 50% improvement in PG lesion size (measured in mm) and proportion of patients achieving resolution of inflammation (an erythema score of 0 and a border thickness of 0 on scales of 0\u20134).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> By week 20, one (25%) of the four patients achieved remission, two showed marked improvement in severity on PGA, and one had slight improvement. One patient showed a 98% decrease in lesion size; two other patients evidenced a decrease in the number of small lesions as well as improvements in primary lesion sizes, but did not surpass the 50% criterion. All four patients showed improved erythema scores during treatment, though only one patient showed a complete resolution of inflammation.<\/jats:p><jats:p><jats:bold>Limitations\u2002<\/jats:bold> It may be difficult to generalize the results of this study to a larger population of patients with PG due to the small sample size and lack of a control group. A longer treatment interval might have been required. Safety and efficacy of long\u2010term therapy is unknown.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> In this pilot study it appears that alefacept treatment may significantly reduce PG severity levels as evidenced by improvement in PGA, Subject Global Assessment, and inflammation scores in all patients. Alefacept may be a safe and effective alternative to current systemic immunosuppressants used to treat PG. Double\u2010blinded, controlled trials are necessary to further evaluate the safety and effectiveness of this treatment.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2008.02680.x","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T22:00:50Z","timestamp":1207087250000},"page":"943-949","source":"Crossref","is-referenced-by-count":32,"title":["An open\u2010label pilot study of alefacept for the treatment of pyoderma gangrenosum"],"prefix":"10.1111","volume":"22","author":[{"given":"CE","family":"Foss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AR","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Inabinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JL","family":"Jorizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,14]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"WinesN WinesM RymanW.Understanding pyoderma gangrenosum: a review.MedscapeJune2001."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200001000-00004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0560.2003.00024.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90285-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.006"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4049\/jimmunol.135.3.1624","article-title":"T cell activation via CD2 (T11, gp50) molecules: accessory cells are required to trigger T cell activation via CD2 D66 plus CD2\u20109.6\/T11(1): epitopes","volume":"135","author":"Brottier P","year":"1985","journal-title":"J Immunol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90039-4"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1988.tb03035.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.4049\/jimmunol.144.5.1591","article-title":"Increase in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation","volume":"144","author":"June CH","year":"1990","journal-title":"J Immunol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830210931"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830210828"},{"key":"e_1_2_6_13_2","first-page":"2023","article-title":"Aruffo A, Ledbetter JA","volume":"148","author":"Kanner SB","year":"1992","journal-title":"J Immunol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/329846a0"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/329840a0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.166.4.923"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230119"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1697984"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.140.5.1401","article-title":"Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA\u20103, CD2, and LFA\u20101) and three other molecules (UCHL1, CDw29, and Pgp\u20101) and have enhanced IFN\u2010gamma production","volume":"140","author":"Sanders ME","year":"1988","journal-title":"J Immunol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/339312a0"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198003000-00003"},{"key":"e_1_2_6_22_2","first-page":"148","article-title":"Successful treatment of postoperative pyoderma gangrenosum with cyclosporine","volume":"16","author":"Schofer H","year":"2002","journal-title":"JEADV"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/095466301750163527"},{"key":"e_1_2_6_24_2","first-page":"5","article-title":"A review of thalidomide's history and current dermatological applications","volume":"9","author":"Perri AJ","journal-title":"Dermatol Online J"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory Bowel disease","volume":"98","author":"Reguerio M","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","unstructured":"MimouniD AnhaltGJ KoubaDJ NousariHC.Infliximab for peristomal pyoderma gangrenosum.2003;148:813\u2013816.","DOI":"10.1046\/j.1365-2133.2003.05294.x"},{"key":"e_1_2_6_27_2","first-page":"930","article-title":"Improvement of pyodera gangrenosum and psoriasis associated with Crohn Disease with anti\u2010tumor necrosis factor \u03b1 monoclonal antibody","volume":"137","author":"Tam M","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.02680.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.02680.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T07:17:49Z","timestamp":1697008669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.02680.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,14]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1468-3083.2008.02680.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02680.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,14]]}}}